GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » Capex-to-Operating-Cash-Flow

Accolade (Accolade) Capex-to-Operating-Cash-Flow : 0.35 (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Accolade Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Accolade's Capital Expenditure for the three months ended in Feb. 2024 was $-2.11 Mil. Its Cash Flow from Operations for the three months ended in Feb. 2024 was $5.95 Mil.

Hence, Accolade's Capex-to-Operating-Cash-Flow for the three months ended in Feb. 2024 was 0.35.


Accolade Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Accolade's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade Capex-to-Operating-Cash-Flow Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Accolade Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.71 0.35

Competitive Comparison of Accolade's Capex-to-Operating-Cash-Flow

For the Health Information Services subindustry, Accolade's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's Capex-to-Operating-Cash-Flow Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Accolade's Capex-to-Operating-Cash-Flow falls into.



Accolade Capex-to-Operating-Cash-Flow Calculation

Accolade's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Feb. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-12.482) / -16.169
=N/A

Accolade's Capex-to-Operating-Cash-Flow for the quarter that ended in Feb. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-2.107) / 5.951
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accolade  (NAS:ACCD) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Accolade Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Accolade's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111

Accolade (Accolade) Headlines

From GuruFocus

Accolade Inc CEO Rajeev Singh Sells 7,622 Shares

By GuruFocus Research 06-15-2023

Accolade To Present at Stifel 2023 Cross Sector Insight Conference

By sperokesalga sperokesalga 06-01-2023

Accolade to Webcast Analyst Day on May 8, 2023

By sperokesalga sperokesalga 04-24-2023

Accolade Announces Upcoming Investor Events

By sperokesalga sperokesalga 05-08-2023